Last reviewed · How we verify
aromatase inhibition therapy
Aromatase inhibition therapy works by blocking the enzyme aromatase, which is involved in the production of estrogen.
Aromatase inhibition therapy works by blocking the enzyme aromatase, which is involved in the production of estrogen. Used for Hormone receptor-positive breast cancer.
At a glance
| Generic name | aromatase inhibition therapy |
|---|---|
| Also known as | endocrine therapy, Inhibition therapy, aromatase, Aromatase Inhibition, hormonal therapy, inhibition therapy, aromatase |
| Sponsor | University of Nebraska |
| Drug class | Aromatase inhibitor |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This leads to a decrease in estrogen levels in the body, which can help slow the growth of hormone receptor-positive breast cancer cells. Aromatase inhibitors are often used in combination with other treatments, such as tamoxifen or chemotherapy, to treat breast cancer.
Approved indications
- Hormone receptor-positive breast cancer
Common side effects
- Hot flashes
- Musculoskeletal pain
- Vaginal dryness
Key clinical trials
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (PHASE3)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- Oral Aromatase Inhibitors Modify the Gut Microbiome
- A Study of LY4257496 in Participants With Cancer (OMNIRAY) (PHASE1)
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) (PHASE2)
- An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aromatase inhibition therapy CI brief — competitive landscape report
- aromatase inhibition therapy updates RSS · CI watch RSS
- University of Nebraska portfolio CI